2nd Circ. Won't Revive Elan, Pfizer Investor Row
The Second Circuit on Friday declined to revive a proposed securities class action against drugmakers Elan Corp. PLC and Pfizer Inc. over allegedly misleading statements in a press release about the...To view the full article, register now.
Already a subscriber? Click here to view full article